ASP4058   Click here for help

GtoPdb Ligand ID: 9569

Synonyms: ASP-4058
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: ASP4058 is an orally active, next-generation sphingosine 1-phosphate (S1P) receptor agonist that shows selectivity for S1P1 and S1P5 over other S1P receptors in vitro [4]. Most likely used as the hydrochloride salt (PubChem CID 16755142). Compare this with the non-selective S1P agonist fingolimod, which was the first oral drug to be approved for relapsing forms of MS.
Studies in animal models suggests that ASP4058 may also be beneficial in ameliorating the chronic arterial wall inflammation observed as underlying intracranial aneurysm (IA) [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 76.83
Molecular weight 442.09
XLogP 6.12
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CC(C(F)(F)F)Oc1ccc(cc1C(F)(F)F)c1onc(n1)c1ccc2c(c1)nc[nH]2
Isomeric SMILES C[C@@H](C(F)(F)F)Oc1ccc(cc1C(F)(F)F)c1onc(n1)c1ccc2c(c1)nc[nH]2
InChI InChI=1S/C19H12F6N4O2/c1-9(18(20,21)22)30-15-5-3-11(6-12(15)19(23,24)25)17-28-16(29-31-17)10-2-4-13-14(7-10)27-8-26-13/h2-9H,1H3,(H,26,27)/t9-/m0/s1
No information available.
Summary of Clinical Use Click here for help
ASP4058 has completed a Phase 1 clinical trial (NCT01998646) in healthy subjects.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01998646 A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses Phase 1 Interventional Astellas Pharma Inc